Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a California-based (1992) and Delaware-incorporated (1996) drug company aimed at discovering, developing, and future marketing of medications for neurological and endocrine-related diseases and disorders. The company currently has eight programs in various stages of research and development, five of which are in clinical development. The product pipeline with their respective indications is as follows:

1. Clinical Development

a. GnRH Antagonist вЂ" endometriosis and benign prostatic hyperplasia

b. CRF1 Antagonsit вЂ" mood disorders, irritable bowel syndrome

c. CRF2 Peptide Antagonist (Urocortin) вЂ" cardiovascular

2. Research

a. sNRI вЂ" depression, stress, pain, and urinary incontinence

b. Glucose-dependent Insulin Secretagogues вЂ" Type II Diabetes

c. Ion Channel Blocker вЂ" chronic pain

3. Subject to regulatory review

a. Indiplon 5 & 10 mg capsules вЂ" insomnia

Neurocrine Biosciences has also entered into collaborative research with GlaxoSmithKline (CRF1 Antagonist) and Dainippon Sumitomo Pharma Co. (Indiplon). The company has been issued 66 US patents for their products, formulations, SOPs, libraries and more as well as In-licensed technologies to complement ongoing research and trials since 1998. They currently rely on contract manufacturers and third parties in anticipation to future marketing and mitigate risks. Currently, the company has 135 employees, 95% are full-time and 30% hold a PhD or MD degrees.

Neurocrine Biosciences, Inc. is an infant company.